Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
AI, Machine Learning & Computational Drug Design | Q&As & Interviews

Interview with Jissy Akkarapattiakal Kuriappan, Principal Investigator, Drug Discovery at Alembic Pharmaceuticals

Edited by Tom Cohen | 12 May 2023
Jissy Akkarapattiakal Kuriappan, Principal Investigator, Drug Discovery at Alembic Pharmaceuticals, discusses using AI to promote drug discovery, the problem with using AI as a black box, and whether AI and ML are a worthwhile investment.
https://youtu.be/v2CP_2hbNPU

Visit our Discovery Portal to learn more about the latest research into drug design, development, and more. If you’d like to register your interest for Oxford Global‘s upcoming conference, Organ Modelling 2023, click here.

Get your weekly dose of industry news?here?and keep up to date with the latest?‘Industry Spotlight’ posts.?For other Discovery content, please visit the?Discovery Content Portal.

Related Resources

New Trailblazer Profluent Launches its AI-enabled OpenCRISPR-1 to Edit the Human Genome

Profluent successfully combined large language models (LLMs) and CRISPR for an open-source AI gene editing project which could reshape CRISPR treatment options.
Read More

Novo Nordisk Foundation and NVIDIA to Launch a State-of-the-Art National AI Research Centre

Novo Nordisk and NVIDIA join forces to build an AI supercomputer which will be housed in Denmark's national centre for AI innovation.
Read More

Related Online Activities

Join the conversation with our upcoming Monthly Science Exchanges and Webinars:
02/09/24
Overcoming The Challenges Of Multi-Omics Data Integration
01/10/24
The Challenges In Integrating AI Into Biomarker Research